Glutamate–urea–lysine (KUE)-based moieties were introduced into this probe as a ligand for prostate-specific membrane antigen (PSMA), which was overexpressed in >90% of prostate cancer cells. The gene discussed is FOLH1; the disease is prostate carcinoma.